ABSTRACT
This article takes the reader through a journey of the history of the phenotypic tests for hemostasis and thrombosis starting from the most simple (which were based on the visual inspection and recording of the time needed for native whole blood to clot) to the more complex ones based on the addition to plasma of exogenous substances, use of sophisticated coagulometers or synthetic substrates, and use of computer software to record coagulation times or visualize coagulation tracings and thrombin generation curves. One can see how the simple tests evolved over the years and how such old and time-honored tests as thrombin generation and thromboelastography, devised more than 50 years ago and neglected for many years, are now gaining momentum thanks to the progress made by the technology combined with a better understanding of the coagulation mechanisms. This progress notwithstanding, it should be realized that current tests are still somewhat far from being adequate to investigate hemostasis and thrombosis. The challenge in the future will be to devise newer tests mimicking more closely what occurs in vivo.
KEYWORDS
PT - APTT - coagulation tests - thrombin generation - synthetic substrates
REFERENCES
1
Langdell R D, Wagner R H, Brinkhous K M.
Effect of anti-hemophilic factor on one stage clotting tests: a presumptive test for hemophilia and a simple one-stage anti-hemophilic assay procedure.
J Lab Clin Med.
1953;
41
637-647
2
Bell W N, Alton H G.
A brain extract as a substitute for platelet suspension in the thromboplastin generation time.
Nature.
1954;
174
880-881
3
Proctor R R, Rapaport S I.
The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies.
Am J Clin Pathol.
1961;
36
212-219
4
Margolis J.
The kaolin clotting time. A rapid one-stage method for diagnosis of coagulation defects.
J Clin Pathol.
1958;
11
406-409
5
Conley C L, Hartmann R C.
A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus.
J Clin Invest.
1952;
31
621-622
6
Bowie E J, Thompson Jr J H, Pascuzzi C A, Owen Jr C A.
Thrombosis in systemic lupus erythematosus despite circulating anticoagulants.
J Lab Clin Med.
1963;
62
416-430
7
Basu D, Gallus A, Hirsh J, Cade J.
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.
N Engl J Med.
1972;
287
324-327
8
Van der Velde E A, Poller L.
The APTT monitoring of heparin–the ISTH/ICSH collaborative study.
Thromb Haemost.
1995;
73
73-81
9
Dahlbäck B, Carlsson M, Svensson P J.
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
Proc Natl Acad Sci U S A.
1993;
90
1004-1008
10
Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci P M.
A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.
Blood.
2004;
104
3631-3634
11
Hron G, Eichinger S, Weltermann A, Quehenberger P, Halbmayer W M, Kyrle P A.
Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time.
J Thromb Haemost.
2006;
4
752-756
12
Lippi G, Favaloro E J.
Activated partial thromboplastin time: new tricks for an old dogma.
Semin Thromb Hemost.
2008;
34
604-611
13
Quick A J.
The prothrombin in hemophilia and in obstructive jaundice.
J Biol Chem.
1935;
109
73-74
14
Butt H R, Allen A V, Bollman J R.
A preparation from spoiled sweet lover which prolong coagulation time of blood.
Proc Staff Meet Mayo Clin.
1941;
16
388-395
15
Poller L.
The effect of the use of different tissue extracts on one-stage prothrombin times.
Acta Haematol.
1964;
32
292-298
16
Poller L.
Standardization of anticoagulant treatment: the Manchester Regional Thromboplastin Scheme.
Br Med J.
1964;
2
564-566
17
Owren P A.
Thrombotest. A new method for controlling anticoagulant therapy.
Lancet.
1959;
2
754-758
18 De Vries S I. Introduction to thrombotest at the Netherlands Thrombosis Service . In: Hemker HC, Loeliger EA, Veltkamp JJ Human Blood Coagulation. Leiden, The Netherlands; Leiden University Press 1969: 314-317
19
Biggs R, Denson K WE.
Standardization of the one-stage prothrombin time for control of anticoagulant therapy.
BMJ.
1967;
1
84-88
20
Bangham D R, Biggs R, Brozovic M, Denson K WE.
Calibration of five different thromboplastins using fresh and freeze-dried plasma.
Thromb Diath Haemorrh.
1973;
29
228-239
21
International Committee on Thrombosis and Haemostasis (ICTH) and International Committee for Standardization in Haematology (ICSH) .
Prothrombin time standardization: report of the export panel on anticoagulant control.
Thromb Haemost.
1979;
42
1073-1114
22 Expert WHO Committee on Biological Standardization .Twenty-eighth report. Technical Report Series, No. 610. Geneva, Switzerland; WHO 1977
23
Hermans J, van den Besselaar A M, Loeliger E A, van der Velde E A.
A collaborative study of reference material for thromboplastins.
Thromb Haemost.
1983;
50
712-717
24
Kirkwood T BL.
Calibration of reference thromboplastins and standardization of the prothrombin time ratio.
Thromb Haemost.
1983;
49
238-244
25 Expert WHO Committee on Biological Standardization .Thirty-third report. Technical Report Series, No. 687. Geneva, Switzerland; WHO 1983
26 Van den Besselaar AMHP, Gralnick HR, Lewis SM Thromboplastin Calibration and Oral Anticoagulant Control. Boston, MA; Martinus Nijhoff Publishers 1984
27
Thomson J M, Tomenson J A, Poller L.
The calibration of second primary international reference preparation for thromboplastin (thromboplastin, human, plain, coded BCT/253).
Thromb Haemost.
1984;
52
336-342
28
Tripodi A, Arbini A, Chantarangkul V, Mannucci P M.
Recombinant tissue factor as substitute for conventional thromboplastin in the prothrombin time test.
Thromb Haemost.
1992;
67
42-45
29
Tripodi A, Chantarangkul V, Braga M et al..
Results of a multicenter study assessing the status of standardization of a recombinant thromboplastin for the control of oral anticoagulant therapy.
Thromb Haemost.
1994;
72
261-267
30
Tripodi A, Chantarangkul V, Negri B, Clerici M, Mannucci P M.
International collaborative study for the calibration of a proposed reference preparation for thromboplastin, human recombinant, plain. On behalf of the Subcommittee on Control of Anticoagulation.
Thromb Haemost.
1998;
79
439-443
31 van den Besselaar A MHP, Poller L, Tripodi A. World Health Organization (WHO) Guidelines for Thromboplastins and Plasma Used to Control Oral Anticoagulant Therapy. WHO Technical Report Series, No. 889. Geneva, Switzerland; WHO 1999
32
Trotter J F, Brimhall B, Arjal R.
Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation.
Liver Transpl.
2004;
10
995-1000
33
Wiesner R, Edwards E, Freeman R et al..
United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor liver.
Gastroenterology.
2003;
124
91-96
34
Tripodi A, Chantarangkul V, Mannucci P M.
The International normalized ratio to prioritize patients for liver transplantation. Problems and possible solutions.
J Thromb Haemost.
2008;
6
243-248
35
Favaloro E J, Adcock D.
Standardization of the INR: How good is your laboratory's INR and can it be improved?.
Semin Thromb Hemost.
2008;
34
593-603
36
Ciavarella N, Eder G, Mannucci P M, Mariani G Italian CISMEL Study Group et al..
Multicenter comparison of nine coagulometers and manual tilt-tube methods for prothrombin time performance.
Clin Lab Haematol.
1983;
5
177-184
37
Triplett D A.
New methods in coagulation.
Crit Rev Clin Lab Sci.
1981;
15
25-84
38
Tripodi A, Mannucci P M.
Clinical evaluation of a fully automated chromogenic method for prothrombin time compared with a conventional coagulation method.
Clin Chem.
1984;
30
1392-1395
39
Tripodi A, Poggio M, Scapellato L, Mannucci P M.
Automated amidolytic method for activated partial thromboplastin time compared with a conventional coagulation method.
Haemostasis.
1989;
19
205-212
40
Frantzen Handeland G, Abildgaard U, Aasen A O.
Simplified assay for antithrombin III activity using chromogenic peptide substrate. Manual and automated method.
Scand J Haematol.
1983;
31
427-436
41
Tang J C, Li S, McGray P, Vecchio A.
Current status of activity assays for tissue plasminogen activator.
Ann N Y Acad Sci.
1984;
434
536-540
42
Tripodi A, Mannucci P M.
Factor VIII activity as measured by an amidolytic assay compared with a one-stage clotting assay.
Am J Clin Pathol.
1986;
86
341-344
43
Franchi F, Tripodi A, Valsecchi C, Mannucci P M.
Functional assay of protein C: comparison of two snake-venom assays with two thrombin assays.
Thromb Haemost.
1988;
60
145-148
44
Macfarlane R G, Biggs R.
A thrombin generation test.
J Clin Pathol.
1953;
6
3-7
45
Hemker H C, Willems G M, Béguin S.
A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes.
Thromb Haemost.
1986;
56
9-17
46
Hemker H C, Wielders S, Kessels H, Béguin S.
Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential.
Thromb Haemost.
1993;
70
617-624
47
Hemker H C, Giesen P L, Ramjee M, Wagenvoord R, Béguin S.
The thrombogram: monitoring thrombin generation in platelet-rich plasma.
Thromb Haemost.
2000;
83
589-591
48
Hartert H.
Blutgerninnungstudien mit der thromboelastographic.
Einen neven Untersuchingsver Farhen Klinische Wocheschrift.
1948;
16
257-260
49
Caprini J A, Traverso C I, Arcelus J I.
Perspectives on thromboelastography.
Semin Thromb Hemost.
1995;
21(Suppl 4)
91-93
50
Gillies B S.
Thromboelastography and liver transplantation.
Semin Thromb Hemost.
1995;
(21 Suppl 4)
45-49
51
Mancuso A, Fung K, Cox D et al..
Assessment of blood coagulation in severe liver disease using thromboelastography: use of citrate storage versus native blood.
Blood Coagul Fibrinolysis.
2003;
14
211-216
Armando TripodiPh.D.
Via Pace 9
20122-Milano, Italy
Email: armando.tripodi@unimi.it